BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BC Extra | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

Santhera Pharmaceuticals Holding AG ( SIX:SANN) said Dario Eklund will succeed Thomas Meier as CEO, effective Dec. 1. Meier will remain on the rare neuromuscular and pulmonary disease company's board and chair its scientific committee. Eklund...
BC Extra | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary outcome for clinical efficacy, in a Phase IIa extension study in boys ages 4-7 with Duchenne muscular dystrophy. Santhera...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BC Extra | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BC Extra | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
BC Week In Review | Apr 12, 2019
Financial News

Santhera raises CHF7.1M in private placement

Santhera said it raised CHF7.1 million ($7.1 million) in a private placement and established a credit facility of up to CHF15 million ($15 million). Santhera Pharmaceuticals Holding AG (SIX:SANN) placed 500,000 registered shares at CHF14.25,...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Week In Review | Mar 29, 2019
Company News

Santhera to seek conditional approval for idebenone in DMD

Santhera said it will submit an application to EMA next quarter seeking conditional approval of idebenone to treat respiratory dysfunction in patients with Duchenne muscular dystrophy who are not using glucocorticoids. EMA's CHMP has twice...
BC Week In Review | Mar 8, 2019
Clinical News

Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC) by 50% for up to six years in the retrospective real-world SYROS study in patients...
Items per page:
1 - 10 of 264
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BC Extra | Nov 5, 2019
Company News

Management tracks: Santhera, Acadia, Aeglea, Entrada, Kleo, Laboratory for Advanced Medicine, Imago, Glympse and Cognition

Santhera Pharmaceuticals Holding AG ( SIX:SANN) said Dario Eklund will succeed Thomas Meier as CEO, effective Dec. 1. Meier will remain on the rare neuromuscular and pulmonary disease company's board and chair its scientific committee. Eklund...
BC Extra | Aug 27, 2019
Clinical News

DMD data to inform Santhera's choice under vamorolone option deal

Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary outcome for clinical efficacy, in a Phase IIa extension study in boys ages 4-7 with Duchenne muscular dystrophy. Santhera...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BC Extra | May 28, 2019
Company News

May 28 Company Quick Takes: Viela finds China partner for rare CNS disorder mAb; plus Santhera, Juvenescence’s Souvien and more

Viela partners with Hansoh on mAb for rare CNS disorder in China  Viela Bio Inc. (Gaithersburg, Md.) granted Hansoh Pharmaceutical Group Co. Ltd. (Lianyungang, China) rights to develop and commercialize Viela's humanized anti-CD19 mAb inebilizumab...
BC Extra | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
BC Week In Review | Apr 12, 2019
Financial News

Santhera raises CHF7.1M in private placement

Santhera said it raised CHF7.1 million ($7.1 million) in a private placement and established a credit facility of up to CHF15 million ($15 million). Santhera Pharmaceuticals Holding AG (SIX:SANN) placed 500,000 registered shares at CHF14.25,...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BC Week In Review | Mar 29, 2019
Company News

Santhera to seek conditional approval for idebenone in DMD

Santhera said it will submit an application to EMA next quarter seeking conditional approval of idebenone to treat respiratory dysfunction in patients with Duchenne muscular dystrophy who are not using glucocorticoids. EMA's CHMP has twice...
BC Week In Review | Mar 8, 2019
Clinical News

Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC) by 50% for up to six years in the retrospective real-world SYROS study in patients...
Items per page:
1 - 10 of 264